Robocath

Founded in 2009 by Dr. Philippe Bencteux, Robocath designs, develops, and markets intelligent robotic solutions dedicated to the treatment of cardiovascular and neurovascular diseases. A key player in the digital transformation of the medical sector, its developments aim to enhance the effectiveness of procedures and improve the safety of interventions through intelligent and connected technologies.
Robocath develops robotic solutions that integrate unique, proprietary bionic technology to secure and optimize coronary angioplasty. This medical procedure involves revascularizing the heart muscle by implanting one or more stents in the arteries that supply it. One such operation is performed every 30 seconds worldwide. These robotic solutions are designed for precise intervention and highly specific movements, all within an enhanced working environment. Thanks to their open architecture, they are compatible with most coronary angioplasty devices and catheterization labs.
Robocath obtained CE marking in 2019 for its first robotic solution, R-One. In a prospective, multicenter, non-randomized, single-arm clinical trial, the efficacy and safety of R-One were demonstrated, with a technical success rate exceeding 95% and no major adverse cardiovascular events (MACE). The solution is currently available in Europe, Africa, and China.
Robocath is the world leader in vascular robotics and continues to develop intelligent digital solutions. Based in Rouen, Robocath has more than 60 employees.

Robotics Artificial Intelligence Robotics Artificial Intelligence